Nedaplatin
Chemical compound
- none
- In general: ℞ (Prescription only)
- Diammine[(hydroxy-κO)acetato(2-)-κO]platinum
- 95734-82-0 Y
- 9796440
- 7972206
- 8UQ3W6JXAN
- D01416 Y
- DTXSID8046878
- Interactive image
- coordination form: Interactive image
- C(C(=O)[O-])[O-].N.N.[Pt+2]
- coordination form: O=C1O[Pt-2]([NH3+])([NH3+])OC1
InChI
- InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1
- Key:GYAVMUDJCHAASE-UHFFFAOYSA-M
Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.
Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.[2]
References
- ^ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219-33. doi:10.1530/ERC-15-0237. hdl:2123/24426. PMID 26113607.
- ^ Johnstone TC, Park GY, Lippard SJ (January 2014). "Understanding and improving platinum anticancer drugs--phenanthriplatin". Anticancer Research. 34 (1): 471–6. PMC 3937549. PMID 24403503.
External links
- "Aqupla アクプラ" (PDF). Shionogi & Co. March 2007. Archived from the original (PDF) on 2004-08-05.
- "Official Shionogi & Co. Website" (in Japanese).
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e